CHANGES IN BODY COMPOSITION AND HEPATIC ELASTOGRAPHY VALUES IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE AT A MEDICAL CENTER IN CARTAGENA – COLOMBIA, DURING THE PERIOD FROM OCTOBER 2023 TO JANUARY 2025

IF 4.4 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Annals of hepatology Pub Date : 2025-09-01 DOI:10.1016/j.aohep.2025.101985

Arturo Jose Viera Oliveros , Ismael Yepes Barreto , Yohana Poveda Salinas , Fernando García del Risco

{"title":"CHANGES IN BODY COMPOSITION AND HEPATIC ELASTOGRAPHY VALUES IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE AT A MEDICAL CENTER IN CARTAGENA – COLOMBIA, DURING THE PERIOD FROM OCTOBER 2023 TO JANUARY 2025","authors":"Arturo Jose Viera Oliveros , Ismael Yepes Barreto , Yohana Poveda Salinas , Fernando García del Risco","doi":"10.1016/j.aohep.2025.101985","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by the accumulation of triglycerides in the liver, linked to cardiometabolic risk factors. Its global prevalence exceeds 30%, rising in parallel with overweight and type 2 diabetes. Visceral fat is associated with systemic inflammation and hepatic fat accumulation. Although elastography is useful for assessing disease progression, its high cost and limited availability necessitate the exploration of alternative tools. The use of body composition parameters has been proposed as potential predictors of disease progression.</div><div>To determine the relationship between changes in body composition and hepatic elastography values in patients with liver disease associated with metabolic dysfunction.</div></div><div><h3>Materials and Methods</h3><div>This was an analytical, observational, and prospective study. Patients over 18 years old with a previous diagnosis of steatotic liver disease were included. All underwent elastography and bioelectrical impedance analysis at baseline and after one year to assess progression risk factors. The patients signed the informed consent.</div></div><div><h3>Results</h3><div>A total of 88 patients were included, 52.3% of whom were women. Initial elastography readings averaged 9.2 kPa; the controlled attenuation parameter (CAP) was 269 dB/m. Factors associated with elevated liver stiffness included type 2 diabetes, chronic kidney disease, AST, APRI, and FIB-4 scores. During follow-up, smoking, alcohol consumption, CAP, and changes in body fat were linked to disease progression. In multivariate analysis, only smoking and baseline CAP were independent predictors.</div></div><div><h3>Conclusions</h3><div>Smoking and baseline CAP were significantly associated with the risk of MASLD progression, suggesting their potential utility in guiding timely interventions.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 ","pages":"Article 101985"},"PeriodicalIF":4.4000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1665268125002108","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction and Objectives

Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by the accumulation of triglycerides in the liver, linked to cardiometabolic risk factors. Its global prevalence exceeds 30%, rising in parallel with overweight and type 2 diabetes. Visceral fat is associated with systemic inflammation and hepatic fat accumulation. Although elastography is useful for assessing disease progression, its high cost and limited availability necessitate the exploration of alternative tools. The use of body composition parameters has been proposed as potential predictors of disease progression.

To determine the relationship between changes in body composition and hepatic elastography values in patients with liver disease associated with metabolic dysfunction.

Materials and Methods

This was an analytical, observational, and prospective study. Patients over 18 years old with a previous diagnosis of steatotic liver disease were included. All underwent elastography and bioelectrical impedance analysis at baseline and after one year to assess progression risk factors. The patients signed the informed consent.

Results

A total of 88 patients were included, 52.3% of whom were women. Initial elastography readings averaged 9.2 kPa; the controlled attenuation parameter (CAP) was 269 dB/m. Factors associated with elevated liver stiffness included type 2 diabetes, chronic kidney disease, AST, APRI, and FIB-4 scores. During follow-up, smoking, alcohol consumption, CAP, and changes in body fat were linked to disease progression. In multivariate analysis, only smoking and baseline CAP were independent predictors.

Conclusions

Smoking and baseline CAP were significantly associated with the risk of MASLD progression, suggesting their potential utility in guiding timely interventions.

查看原文本刊更多论文

2023年10月至2025年1月期间，哥伦比亚卡塔赫纳医疗中心代谢功能障碍相关脂肪变性肝病患者的身体组成和肝脏弹性成像值的变化

代谢功能障碍相关脂肪变性肝病（MASLD）的特征是肝脏中甘油三酯的积累，与心脏代谢危险因素相关。其全球患病率超过30%，与超重和2型糖尿病同时上升。内脏脂肪与全身炎症和肝脏脂肪堆积有关。虽然弹性成像对评估疾病进展是有用的，但其高成本和有限的可用性需要探索替代工具。已提出使用身体成分参数作为疾病进展的潜在预测指标。目的：探讨伴有代谢功能障碍的肝病患者体成分变化与肝弹性图值的关系。材料与方法这是一项分析性、观察性和前瞻性研究。患者年龄超过18岁，既往诊断为脂肪变性肝病。在基线和一年后，所有患者都进行了弹性成像和生物电阻抗分析，以评估进展危险因素。患者在知情同意书上签字。结果共纳入88例患者，其中女性占52.3%。初始弹性图读数平均为9.2 kPa；控制衰减参数为269 dB/m。与肝僵硬度升高相关的因素包括2型糖尿病、慢性肾病、AST、APRI和FIB-4评分。在随访期间，吸烟、饮酒、CAP和体脂变化与疾病进展有关。在多变量分析中，只有吸烟和基线CAP是独立的预测因子。结论吸烟和基线CAP与MASLD进展风险显著相关，提示其在指导及时干预方面的潜在效用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of hepatology 医学-胃肠肝病学

CiteScore

7.90

自引率

2.60%

发文量

183

审稿时长

4-8 weeks

期刊介绍： Annals of Hepatology publishes original research on the biology and diseases of the liver in both humans and experimental models. Contributions may be submitted as regular articles. The journal also publishes concise reviews of both basic and clinical topics.